The ADAPTED project (Alzheimer’s Disease Apolipoprotein Pathology for Treatment Elucidation and Development), led by Fundació ACE, is a research study that investigates the biological mechanisms through which the presence of the APOE gene increases the risk of developing Alzheimer's. The ultimate goal is to determine new treatment and prevention strategies for this disease.
The APOE gene is a protein involved in the transport of cholesterol. Carrying the genetic variant known as APOE4 is one of the most important risk factors for developing Alzheimer's. Although this fact has been known for more than twenty years, the molecular mechanisms by which this happens are still unknown, since it has received less attention from the scientific community so far.
The ADAPTED project, that has a budget of 7 million euros, is funded by IMI (Innovative Medicines Initiative) a public-private consortium between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA), created to boost pharmaceutical innovation in Europe and accelerate the development of more effective and safe medicines.